Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau had 369 shares of Encompass Health common stock withheld at a price of $107.88 per share to cover tax obligations from vesting restricted stock. After this tax-withholding disposition, she directly holds 17,644.061 shares.
Encompass Health Corp executive John Patrick Darby reported routine equity compensation activity. He received a grant of 5,967 non-qualified stock options at $108.06 per share, which become exercisable in equal installments over three years starting March 2, 2027. Separately, 416 shares of common stock were disposed of to satisfy tax withholding obligations tied to the vesting of related restricted stock, rather than through an open-market sale.
Encompass Health Corp President & CEO Mark J. Tarr reported a mix of equity award activity and tax-related share withholding. He received a grant of non-qualified stock options covering 35,461 shares at an exercise price of $108.06 per share. According to the disclosure, these options become exercisable in equal annual installments over a three-year period beginning March 2, 2027.
In a separate transaction, 2,187 shares of Encompass Health common stock were withheld or surrendered at $107.88 per share to satisfy tax withholding obligations tied to the vesting of related restricted stock. After these transactions, Tarr directly held 440,962 shares of common stock.
Encompass Health Corp executive Patrick William Tuer reported two equity-related transactions. He received a grant of 10,502 non-qualified stock options at an exercise price of $108.06 per share, which become exercisable in three equal annual installments starting on March 2, 2027. Separately, 545 shares of common stock at $107.88 per share were withheld to cover tax obligations arising from the vesting of related restricted stock, leaving him with 25,437 directly held shares.
Encompass Health Corp executive Douglas E. Coltharp reported a new stock option grant and a related tax-withholding share disposition. He received a non-qualified stock option for 12,275 shares at $108.06 per share, which becomes exercisable in equal annual installments over three years starting March 2, 2027.
To cover tax obligations from restricted stock vesting, 776 common shares were withheld at $107.88 per share, leaving him with 69,377 directly owned common shares. The filing also lists indirect holdings held through irrevocable trusts and by his spouse, totaling additional baseline share positions.
Encompass Health Corporation filed its annual report describing a growing inpatient rehabilitation business focused on Medicare-funded care. The company operated 173 hospitals across 39 states and Puerto Rico as of December 31, 2025, treating 263,299 discharges with 11,465 licensed beds.
Net operating revenues reached $5.94 billion in 2025, up from $5.37 billion in 2024 and $4.80 billion in 2023, driven mainly by inpatient revenue of $5.76 billion. Medicare and Medicare Advantage together accounted for about 82% of total revenues, underscoring reliance on government reimbursement.
The report highlights strategic priorities of expanding bed capacity and de novo hospitals, deepening joint ventures with acute-care systems, and leveraging technology, data, and AI in post-acute care. Management emphasizes a long-dated, largely fixed-rate debt structure, a $1 billion revolving credit facility, and strong cash flow to fund growth and shareholder returns.
Extensive sections detail reimbursement and regulatory risk, including IRF-PPS rate updates, Medicare audits, False Claims Act exposure, Stark and Anti-Kickback rules, HIPAA/HITECH privacy obligations, and certificate-of-need and Medicaid policy changes that could affect volumes, pricing, and margins.
Encompass Health Corp President and CEO Mark J. Tarr reported a tax-related share disposition. On the transaction date, 2,488 shares of Encompass Health common stock were withheld at $106.15 per share to cover his tax withholding obligations from vesting restricted stock. After this withholding disposition, Tarr directly owned 443,149 shares of Encompass Health common stock, reflecting his ongoing equity stake in the company.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported a small insider share disposition related to equity compensation. On the transaction date, 380 shares of Encompass Health common stock were withheld at a price of $106.15 per share to cover tax obligations from vesting restricted stock, leaving him with 101,542 directly held shares.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported a tax-related share disposition. On the reported date, 506 shares of Encompass Health common stock were withheld or surrendered at $106.15 per share to cover tax withholding obligations from vesting restricted stock. After this tax-withholding disposition, Tuer directly owned 25,982 shares of Encompass Health common stock.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported a Form 4 transaction involving Encompass Health Common Stock. On February 23, 2026, 14,818 shares were disposed of at $106.15 per share under code F, which indicates a tax-withholding disposition to satisfy tax obligations tied to vesting restricted stock, rather than an open-market sale. After this withholding event, he directly owns 70,153 shares, with additional indirect holdings reported through an irrevocable trust, an irrevocable trust for the benefit of his children, and his spouse.